By: chetans@saspinjara.com / August 30, 2024

Merger and Acquisition Report for Closed Deals in the First Half of Calendar Year 2024

Compiled by : SaSPinjara

Contents

Overveiw

Key Insights

Deal Type distribution

Deal Direction distribution

Top 5 Companies Involved

Monthly Breakdown

Conclusion

Access complete M&A data sheet below.

Overview

The dataset from the Pharmacodia Global database provides a comprehensive overview of the merger and acquisition activities that were completed in the first half of the calendar year 2024. The data includes various aspects such as deal titles, principal and partner companies, deal types, directions, and financial details.

Notably, all deals are marked as “Completed”, indicating successful transactions. The *dataset reveals substantial financial engagements in * Total Payment (USD Million), such as the $4300 million acquisition by Cymabay Therapeutics Inc and the $750 million acquisition byIncyte Corp, showcasing the dynamic nature of corporate transactions across different sectors and regions.

Key Insights

Total Number of Deals

Total deals Completed

66

Financial deals Overview (disclosed ones)

*Total Payment in USD

$ 17,295 million

*(For several deals the Total payment amount is not disclosed, due to confidentiality agreements, pending negotiations, or the nature of the deals themselves.)
Data source: Pharmacodia Global

Deal type distribution

  • Acquisitions: Predominantly favored, with 49 deals categorized as acquisitions abroad, 6 deals as abroad to China and 2 deals as acquisitions from China to China.
  • Mergers: Less common, with 7 deals noted as mergers abroad and 1 deal each from China to abroad and China to China.

The chart highlights that high-value deals are predominantly acquisitions and are most commonly conducted in the ‘Abroad to Abroad’ direction. This suggests a strategic focus on expanding or consolidating market presence internationally among the principal companies. Other directions might represent emerging or less prioritized markets in the context of top-value deals.

Deal direction distribution

The above bar chart also highlights that deals directed from abroad to abroad tend to have a higher frequency compared to those directed from Abroad to China.

Top 5 Principal Companies by number of Deals

  1. 2seventy Bio Inc and Carterra Inc: Each involved in 2 deals.
  2. Celltrion IncEli Lilly And Company, and Cymabay Therapeutics Inc: Each involved in 1 deal.

Top 5 Partner Companies by number of Deals

  1. Essential PharmaBristol-Myers Squibb CompanyJohnson & Johnson, and Immunome Inc: Each involved in 2 deals.
  2. Hasten Biopharma Co Ltd: Involved in 1 deal.

Monthly breakdown

The data and visual analysis indicate a steady trend for the number of deals through the months, with a slight dip in February and May, but significant peaks at the beginning and end of the half-year.

The bar chart data visualization clearly illustrates this trend, with January and June showing a higher number of deals compared to other months, particularly February which had the fewest. This information can be useful for planning and resource allocation for the involved parties.

Conclusion :

The first half of 2024 saw a robust number of mergers and acquisitions, predominantly characterized by acquisitions, particularly abroad. The data highlights the active involvement of key players in the industry, such as 2seventy Bio Inc and Carterra Inc, which were the most involved principal companies. This report provides a clear snapshot of the M&A landscape in this period, useful for stakeholders analyzing market trends, investment opportunities, and competitive dynamics in the industry.

Latest Report

Previous post
Pharmacodia Global Weekly Drug R & D Progress Report (Innovative Drugs)(10-08-2024 to 16-08-2024)
Next Post
Pharmacodia Global Weekly China Drugs R & D Report (Generic Drugs)

Copyright © 2022. Designed by WordPressRiver

× How can I help you?